Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Orforglipron (Foundayo)

Foundayo

Animal replicated

FDA-approvedGLP-1 Receptor Agonist Small Molecule Anti-Obesity Drug

RouteOralFDA-approved

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: Non-Peptide Small Molecule — GLP-1 Receptor Agonist — FDA Approved April 2026 — First Oral GLP-1 Without Food/Water Restrictions — GLP-1 Receptor Agonist, Small Molecule, Anti-Obesity Drug.
Why people use it: Used primarily for weight loss and gut health.

If you only read one thing

Orforglipron (FDA-approved April 2026 as Foundayo) is the first non-peptide oral GLP-1 receptor agonist. It achieves roughly 11-12% weight loss at the highest dose — meaningfully less than injectable semaglutide (15%) and substantially less than tirzepatide (22%). The trade-off is accessibility: a pill taken any time, with or without food, that requires no injection, no refrigeration for storage before dispensing, and no prior healthcare encounter for needle training. The billions of people with obesity who will not inject themselves have a real pharmacological option for the first time. The question that matters going forward is not 'is orforglipron as good as tirzepatide?' It is: 'how many more people will get effective GLP-1 therapy because a pill exists?'

Check interactions →

Published literature

3human RCTs0human studies1animal0in vitro

Counts include oral orforglipron Phase 2 and pivotal oral Phase 3 obesity/T2D evidence; no injectable route evidence is implied for this small molecule.

Evidence reality check

Human evidence

3 human studies

3 randomized; 0 observational.

Preclinical base

1 lab signal

1 animal; 0 in-vitro/mechanistic.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Weight Loss & Metabolic Gut & Digestive

Properties

Active malignancy: caution✓ FDA-approved✓ Human RCTNot injectable

Evidence

CAnimal replicated

The Small Molecule Distinction

GLP-1 receptor agonists before orforglipron were all modified peptides (semaglutide, liraglutide, tirzepatide, exenatide). Peptides cannot be taken orally without special formulation because they are cleaved by GI peptidases and degraded by gastric acid. Oral semaglutide (Rybelsus) circumvents this with the SNAC absorption enhancer but requires a strict 30-minute fast and small water amount. Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist — the same receptor, fundamentally different chemistry. Small molecules are not degraded by peptidases or gastric acid, making unrestricted oral delivery straightforward.

ATTAIN-1 Results (NEJM, Sept 2025)

Phase 3; n=3,127; 72 weeks; obesity without diabetes; three doses vs placebo. At 72 weeks: 6 mg: -7.5% body weight; 12 mg: -8.4%; 36 mg: -11.2% vs -2.1% placebo (all p<0.001). Efficacy estimand (had all participants remained on treatment): 36 mg achieved -12.4% (-27.3 lbs). 59.6% of 36mg group achieved ≥10% weight loss; 39.6% ≥15%; 18.4% ≥20%. Waist circumference, systolic BP, triglycerides, and non-HDL cholesterol all significantly improved. Safety profile consistent with injectable GLP-1 class (nausea, constipation, diarrhea, vomiting). No hepatic safety signal.

vs Injectable GLP-1 Efficacy

The honest comparison: orforglipron 36mg produces -11.2% to -12.4% weight loss at 72 weeks. Injectable semaglutide weekly (STEP-1): -14.9% at 68 weeks. Tirzepatide 15mg (SURMOUNT-1): -22.5% at 72 weeks. Orforglipron is less potent than injectable semaglutide and substantially less potent than tirzepatide. The argument for orforglipron is not maximum weight loss — it is accessibility, adherence, and the billions of people who will not or cannot self-inject.

ATTAIN-MAINTAIN

Phase 3b; December 2025 positive topline; published in Nature Medicine 2026. Design: participants who completed 72 weeks on the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide) in SURMOUNT-5 were re-randomized to orforglipron or placebo for 52 weeks. Orforglipron met the primary and all key secondary endpoints for superior weight maintenance vs placebo after switching from injectables. Clinically significant finding: orforglipron can be used as a maintenance step-down from injectable GLP-1 therapy, potentially enabling injection holiday while sustaining results.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

Metformin

Same class · Small Molecule

The TAME Trial: The First FDA-Recognized Study to Use 'Aging' as a Drug Indication. The Bannister Study: Diabetics on Metformin Outlive Non-Diabetics. The 2024 Cell Primate Paper: 6.1-Year Brain Aging Regression. The Exercise Controversy: Metformin Blunts the Mitochondrial Benefits of Training. B12 Depletion: The Most Important Long-Term Safety Issue. Metformin vs Rapamycin: The Same mTOR Pathway, Different Entry Points. Who Benefits Most. Who Shouldn't Use It.

Retatrutide

Same class · Anti-Obesity Drug

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

Survodutide